Main Line Health has named Charles Antzelevitch, PhD, FACC, FAHA, FHRS, executive director of the cardiovascular research program at Lankenau Institute for Medical Research and director of research at Lankenau Heart Institute. Dr. Antzelevitch is an internationally recognized expert in cardiac electrophysiology and arrhythmia syndromes. In his new role at Main Line Health, he will assemble a cardiovascular research team of clinical investigators and basic scientists to advance understanding of the underlying mechanisms of cardiac arrhythmias and to translate these discoveries into novel approaches to therapy.
Dr. Antzelevitch joins Main Line Health after more than 31 years as executive director, director of research, and Gordon K. Moe scholar (endowed chair in experimental cardiology) at the Masonic Medical Research Laboratory in Utica, NY. He also holds an academic appointment as professor of pharmacology at SUNY Upstate Medical University in Syracuse, NY.
Since the start of his scientific career, Dr. Antzelevitch has been awarded more than $24 million in research grants. Together with his research colleagues, Dr. Antzelevitch discovered and characterized the physiological basis for how life-threatening arrhythmias begin. Dr. Antzelevitch’s contributions to the scientific literature on cardiac arrhythmias include nearly 500 original articles and book chapters and 6 edited reference texts. His achievements have been widely recognized, with many professional honors.
Dr. Antzelevitch has been a member of ASPET since 2013. He is a member of the Division for Cardiovascular Pharmacology.
Last updated: August 31, 2015